Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF 16.40
0.00 (0.00%)
Apr 22, 2026, 5:30 PM CET
Newron Pharmaceuticals Employees
Newron Pharmaceuticals had 27 employees as of December 31, 2025. The number of employees increased by 5 or 22.73% compared to the previous year.
Employees
27
Change (1Y)
5
Growth (1Y)
22.73%
Revenue / Employee
659.51K CHF
Profits / Employee
-456.51K CHF
Market Cap
341.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 27 | 5 | 22.73% |
| Dec 31, 2024 | 22 | 0 | - |
| Dec 31, 2023 | 22 | -1 | -4.35% |
| Dec 31, 2022 | 23 | -2 | -8.00% |
| Dec 31, 2021 | 25 | 2 | 8.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Basilea Pharmaceutica AG | 189 |
| Molecular Partners AG | 134 |
| Santhera Pharmaceuticals Holding AG | 79 |
| BioVersys AG | 33 |
| Xlife Sciences AG | 17 |
| Addex Therapeutics | 2 |
Newron Pharmaceuticals News
- 4 weeks ago - Newron Presents 2025 Financial Results and Provides 2026 Outlook - Business Wire
- 4 weeks ago - Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) - Business Wire
- 4 weeks ago - Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract - Business Wire
- 5 weeks ago - Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting - Business Wire
- 2 months ago - Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program - Business Wire
- 2 months ago - Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia - Business Wire
- 3 months ago - EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Business Wire
- 3 months ago - Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent - Business Wire